S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
Log in

NASDAQ:MNLOMenlo Therapeutics News Headlines

$1.40
-1.19 (-45.95 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.28
Now: $1.40
$1.47
50-Day Range
$2.18
MA: $3.64
$5.53
52-Week Range
$1.28
Now: $1.40
$7.87
Volume10.07 million shs
Average Volume710,991 shs
Market Capitalization$34.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84

Headlines

Menlo Therapeutics (NASDAQ MNLO) News Headlines

Source:
DateHeadline
Menlo Late-stage Trial On Prurigo Nodularis Fails To Meet Main Goal; Stock DownMenlo' Late-stage Trial On Prurigo Nodularis Fails To Meet Main Goal; Stock Down
www.nasdaq.com - April 6 at 3:32 PM
Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo NodularisMenlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis
finance.yahoo.com - April 6 at 7:37 AM
Menlos partner LEO Pharma remedies Finacea Foam supply issuesMenlo's partner LEO Pharma remedies Finacea Foam supply issues
seekingalpha.com - April 2 at 3:55 PM
Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply IssuesMenlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues
finance.yahoo.com - April 2 at 3:55 PM
 Brokerages Anticipate Menlo Therapeutics Inc (NASDAQ:MNLO) Will Announce Quarterly Sales of $2.14 Million Brokerages Anticipate Menlo Therapeutics Inc (NASDAQ:MNLO) Will Announce Quarterly Sales of $2.14 Million
www.americanbankingnews.com - April 1 at 2:48 AM
Menlo Security Offers Free Cloud Security and Phishing Protection Licenses to Secure Remote WorkersMenlo Security Offers Free Cloud Security and Phishing Protection Licenses to Secure Remote Workers
www.businesswire.com - March 30 at 6:41 PM
 Brokerages Anticipate Menlo Therapeutics Inc (NASDAQ:MNLO) to Announce -$0.69 EPS Brokerages Anticipate Menlo Therapeutics Inc (NASDAQ:MNLO) to Announce -$0.69 EPS
www.americanbankingnews.com - March 30 at 8:28 AM
Menlo Therapeutics Inc (NASDAQ:MNLO) Short Interest UpdateMenlo Therapeutics Inc (NASDAQ:MNLO) Short Interest Update
www.americanbankingnews.com - March 26 at 8:58 PM
Menlo Therapeutics Inc (NASDAQ:MNLO) Given Average Rating of "Buy" by AnalystsMenlo Therapeutics Inc (NASDAQ:MNLO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 25 at 2:55 PM
Menlo Therapeutics (NASDAQ:MNLO) Receives New Coverage from Analysts at BarclaysMenlo Therapeutics (NASDAQ:MNLO) Receives New Coverage from Analysts at Barclays
www.americanbankingnews.com - March 25 at 8:55 AM
New finance chief at Menlo TherapeuticsNew finance chief at Menlo Therapeutics
seekingalpha.com - March 24 at 8:33 AM
Menlo Therapeutics provides business update amid Covid-19Menlo Therapeutics provides business update amid Covid-19
seekingalpha.com - March 20 at 9:36 AM
Menlo Therapeutics Provides a Business Update in the Context of COVID-19Menlo Therapeutics Provides a Business Update in the Context of COVID-19
finance.yahoo.com - March 20 at 9:36 AM
Analysts Set Expectations for Menlo Therapeutics Incs FY2023 Earnings (NASDAQ:MNLO)Analysts Set Expectations for Menlo Therapeutics Inc's FY2023 Earnings (NASDAQ:MNLO)
www.americanbankingnews.com - March 16 at 2:24 AM
Menlo Therapeutics EPS beats by $0.56Menlo Therapeutics EPS beats by $0.56
seekingalpha.com - March 12 at 11:41 PM
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended December 31, 2019
finance.yahoo.com - March 12 at 8:40 AM
Menlo Therapeutics and Foamix Pharmaceuticals...Menlo Therapeutics and Foamix Pharmaceuticals...
www.benzinga.com - March 9 at 1:25 PM
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsMenlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
finance.yahoo.com - March 9 at 8:24 AM
Menlo Therapeutics up 20% ahead of Foamix merger & key data readoutMenlo Therapeutics up 20% ahead of Foamix merger & key data readout
seekingalpha.com - March 6 at 1:39 PM
Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial ResultsMenlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - March 3 at 6:30 PM
Menlo Is A Good Bet Reflecting The Upcoming CatalystsMenlo Is A Good Bet Reflecting The Upcoming Catalysts
seekingalpha.com - March 3 at 1:15 PM
Menlos chronic pruritus Phase 2 trial fails to meet primary endpointMenlo's chronic pruritus Phase 2 trial fails to meet primary endpoint
seekingalpha.com - February 26 at 1:01 PM
Menlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goalsMenlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goals
www.marketwatch.com - February 26 at 1:01 PM
Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginMenlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
finance.yahoo.com - February 26 at 8:01 AM
Menlo Therapeutics to Host Conference Call...Menlo Therapeutics to Host Conference Call...
www.benzinga.com - February 26 at 12:13 AM
Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginMenlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin
finance.yahoo.com - February 25 at 7:13 PM
Shareholders back Foamix/Menlo tie-upShareholders back Foamix/Menlo tie-up
seekingalpha.com - February 6 at 5:16 PM
Foamix and Menlo Announce Shareholder Approval of Proposed MergerFoamix and Menlo Announce Shareholder Approval of Proposed Merger
finance.yahoo.com - February 6 at 5:16 PM
Stock To Watch: Menlo Therapeutics (MNLO) Awaits Serlopitant Data This Month Stock To Watch: Menlo Therapeutics (MNLO) Awaits Serlopitant Data This Month
www.rttnews.com - February 5 at 1:48 PM
Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of DermatologyMenlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of Dermatology
finance.yahoo.com - February 5 at 9:49 AM
Steven Cohens Point72 Piles Into Menlo TherapeuticsSteven Cohen's Point72 Piles Into Menlo Therapeutics
finance.yahoo.com - January 22 at 10:39 PM
Steven Cohen's Point72 Piles Into Menlo TherapeuticsSteven Cohen's Point72 Piles Into Menlo Therapeutics
finance.yahoo.com - January 22 at 5:39 PM
Menlo Therapeutics up 9% after hours on Cohen stakeMenlo Therapeutics up 9% after hours on Cohen stake
seekingalpha.com - January 21 at 8:58 PM
Did You Miss Menlo Therapeutics's (NASDAQ:MNLO) 26% Share Price Gain?Did You Miss Menlo Therapeutics's (NASDAQ:MNLO) 26% Share Price Gain?
finance.yahoo.com - January 16 at 1:11 PM
Hedge Funds Are Selling Menlo Therapeutics Inc. (MNLO)Hedge Funds Are Selling Menlo Therapeutics Inc. (MNLO)
finance.yahoo.com - December 17 at 7:16 PM
Menlo Therapeutics Inc. Common Stock (MNLO) Institutional HoldingsMenlo Therapeutics Inc. Common Stock (MNLO) Institutional Holdings
www.nasdaq.com - December 15 at 12:01 AM
Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare ConferenceMenlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference
finance.yahoo.com - November 27 at 9:40 AM
BRIEF-Foamix And Menlo Therapeutics To MergeBRIEF-Foamix And Menlo Therapeutics To Merge
www.msn.com - November 11 at 10:30 PM
Menlo, Foamix stocks set for selloffs after all-stock merger dealMenlo, Foamix stocks set for selloffs after all-stock merger deal
finance.yahoo.com - November 11 at 12:29 PM
Foamix to merge with Menlo TherapeuticsFoamix to merge with Menlo Therapeutics
seekingalpha.com - November 11 at 7:28 AM
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsFoamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
feeds.benzinga.com - November 11 at 6:27 AM
Menlo Therapeutics And Serlopitant In Pruritogenic Prurigo Nodularis: On TrackMenlo Therapeutics And Serlopitant In Pruritogenic Prurigo Nodularis: On Track
seekingalpha.com - November 1 at 5:25 PM
Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program UpdatesMenlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates
finance.yahoo.com - October 31 at 7:54 PM
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo NodularisMenlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis
finance.yahoo.com - October 29 at 9:26 AM
Menlo Therapeutics to Host Investor Day October 29, 2019Menlo Therapeutics to Host Investor Day October 29, 2019
finance.yahoo.com - October 22 at 10:49 AM
Heres Why Were Watching Menlo Therapeuticss (NASDAQ:MNLO) Cash Burn SituationHere's Why We're Watching Menlo Therapeutics's (NASDAQ:MNLO) Cash Burn Situation
finance.yahoo.com - October 16 at 5:31 PM
Here's Why We're Watching Menlo Therapeutics's (NASDAQ:MNLO) Cash Burn SituationHere's Why We're Watching Menlo Therapeutics's (NASDAQ:MNLO) Cash Burn Situation
finance.yahoo.com - October 16 at 12:31 PM
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology MeetingMenlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting
finance.yahoo.com - October 11 at 2:19 PM
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with ChronicMenlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic
www.bloomberg.com - September 29 at 10:33 PM
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare ConferenceMenlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 4:07 PM
This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel